Concepedia

pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil

Patricia Barco, Rosilene Fressatti Cardoso, Rosário Dominguez Crespo Hirata, Clarice Queico Fujimura Leite, J. R. C. Pandolfi, Daisy Nakamura Sato, Mako Shikama, Fabrício Freire de Melo, Elsa Masae Mamizuka, Paula Aline Zanetti Campanerut,

Journal of Antimicrobial Chemotherapy · 2006 · 56 citations · 39 references

DOIFull text

Open access

Abstract

These results contribute to the knowledge of the molecular mechanism of pyrazinamide resistance in Brazil and also expand the profile of pncA mutations worldwide. The MABA was successfully used to determine the MICs of pyrazinamide.

References

39

Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium

L A Collins, Scott G. Franzblau · Antimicrobial Agents and Chemotherapy · 1997 · 1.6K citations · Full text

Rapid, Low-Technology MIC Determination with Clinical <i>Mycobacterium tuberculosis</i> Isolates by Using the Microplate Alamar Blue Assay

Scott G. Franzblau, Richard Witzig, James C. McLaughlin et al. · Journal of Clinical Microbiology · 1998 · 940 citations · Full text

, , +17

Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

Angelo Scorpio, Ying Zhang · Nature Medicine · 1996 · 715 citations

, , +9

The action of antituberculosis drugs in short-course chemotherapy

D.A. Mitchison · Tubercle · 1985 · 510 citations

, , +9

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

Yongwei Zhang · Journal of Antimicrobial Chemotherapy · 2003 · 471 citations · Full text

, , +16